VTRSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Viatris Inc
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$18.26−0.39 (-2.12%)
Close on Oct 19, 2026
- Market cap
- $21.24B
- P/E (TTM)
- –
- Dividend yield
- 2.63%
Share price
+$8.09 (+79.55%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.EarningsEx-dividend
Viatris Inc grew revenue 4.4% to $14.74B over the twelve months to Jun 30, 2026. Free cash flow was $1.95B, up 11.6% from a year earlier.
Revenue
$14.74B
+4.4% vs. a year earlier
Operating income
-$87.30M
TTM Q2 2026
Free cash flow
$1.95B
+11.6% vs. a year earlier
EPS, diluted
-$3.00
FY2025
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $21.24B
- P/E ratio
- –
- Price to sales
- 1.44
- Price to book
- –
- Dividend yield
- 2.63%
- Free cash flow yield
- 9.20%
Fundamentals
- Revenue
- $14.74B
- EPS, diluted
- -$3.00
- Free cash flow
- $1.95B
- Diluted shares
- 1.16B
Nine years at a glance
Fiscal years 2017 to 2025 and trailing twelve months, USD
Revenue
$14.74B+4.4% YoY
Gross profit
$5.13B-0.7% YoY
Operating income
-$87.30M
EPS, diluted
–
Free cash flow
$1.95B+11.6% YoY
Reported periodTrailing twelve months